Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stroke drug shrink brain damage after clot removal?

NCT ID NCT07800572

Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This trial tests whether anisodine hydrobromide can reduce brain damage in people who have had a severe ischemic stroke and are undergoing a procedure to remove the blood clot. The study includes about 200 adults aged 18 to 80 with a blockage in a major artery in the front of the brain. Participants receive either the drug or a placebo by intravenous infusion twice daily for 7 days, and researchers measure the size of the stroke-related brain injury and how well patients recover over 90 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anisodine hydrobromide, a drug given by intravenous infusion twice daily for 7 days after stroke treatment
What this could lead to
If it works, this could point toward a new treatment to limit brain damage and improve recovery after a severe ischemic stroke.
What could go wrong
This is an early phase 2 trial, so the drug may not prove effective or safe. The results will need confirmation in larger studies before it could become a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years * Anterior-circulation large-vessel occlusion involving the intracranial ICA, M1, or proximal/dominant M2 * Eligible for endovascular treatment within 24 hours of last known well * Baseline NIHSS score ≥6 * Baseline ASPECTS ≥6 * Pre-stroke mRS score 0-1 * Written informed consent provided by the participant or legally authorized representative Exclusion Criteria: * Intracranial hemorrhage on baseline imaging * Significant bleeding disorder or coagulopathy * Vascular anatomy unsuitable for EVT * Pregnancy, breastfeeding, or planned pregnancy within 90 days * Known hypersensitivity or severe intolerance to anisodine hydrobromide * Contraindication to anticholinergic drugs * Severe arrhythmia or hemodynamic instability * Severe psychiatric disorder, dementia, or impaired consciousness precluding consent or follow-up * Malignancy or other severe systemic disease with a life expectancy \<90 days * Participation in another clinical trial within 30 days before enrollment or concurrently * Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anji County People's Hospital

    RECRUITING

    Huzhou, China

  • Anyang People's Hospital

    NOT_YET_RECRUITING

    Anyang, China

  • Jiuquan People's Hospital

    RECRUITING

    Jiuquan, China

  • Lishui Central Hospital

    NOT_YET_RECRUITING

    Lishui, China

  • Shangqiu First People's Hospitl

    RECRUITING

    Shangqiu, China

  • Suzhou Municipal Hospital of Anhui Province

    RECRUITING

    Suzhou, China

  • Taizhou Enze Medical Center (Group) Enze Hospital

    RECRUITING

    Taizhou, China

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, China

  • Xuanwu Hospital，Capital Medical University

    RECRUITING

    Beijing, China

  • Zhangpu County Hospital

    RECRUITING

    Zhangzhou, China

  • Zibo Central Hospital

    RECRUITING

    Zibo, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.